Research and Development
Aging is a natural part and the “last mile” of human development program. We pioneer ways to understand, measure and, ultimately, control its progression. We view aging as a dynamic process and employ big data from biobanks and large medical studies. The combination of analytical approaches originating from the dynamical systems theory and physics of complex systems yields predictive models of aging for biomarkers of aging discovery. Ultimately, the GERO-dynamics principles can be used to suggest and efficiently test state-of-art therapies aimed at the aging process itself.
Aging is a significant and constantly growing burden on economies and societies and the single most important risk factor for disease, disability and mortality worldwide. Between 2015 and 2030, the number of people in the world aged 60 years or over is projected to grow by 56%, from 901 million to 1.4 billion, and by 2050 the global population of older people is projected to more than double its size in 2015, reaching nearly 2.1 billion. Globally, population aged 60 or over is growing faster than all younger age groups.
The growing number of scientists and pharmaceutical experts believe that a much more promising strategy is trying to solve the underlying cause or risk factor of all these diseases — aging.
Though huge resources are involved in research dedicated to the development of therapies against almost each of the age related diseases, the effect of the potential success in each of the fields would not dramatically change human population lifespan. According to Taeuber paradox, if all the cancer in the world is cured, human will leave on average only 3 years longer, and 6 years longer if we cure all the cardiovascular diseases.
Investigations of aging dynamics and control in circulating blood plasma metabolites and proteins comprise an especially exciting opportunity. Experiments with young blood transfusion (Villeda et al., 2014) and parabiosis (Conboy & Rando, 2014), along with early clinical trials results, suggest that human blood contains biological signals responsible for intracellular communication and synchronization and associated with development and aging. It is, therefore, promising to use aging dynamics models to identify putative regulators of aging among circulating targets. Once identified, the harmful proteins could be selectively removed from circulation by a medical device via therapeutic apheresis – extracorporeal adsorption of unwanted substances from blood.
We used our modeling platform to identify putative aging regulators
and gained first promising results in preclinical testing.
Contact us to learn more.